Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares Purchased by Sei Investments Co.

Sei Investments Co. lifted its position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 4.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,477 shares of the company’s stock after purchasing an additional 477 shares during the quarter. Sei Investments Co.’s holdings in Biohaven Pharmaceutical were worth $1,215,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BHVN. Capital International Investors raised its stake in Biohaven Pharmaceutical by 4.6% during the 1st quarter. Capital International Investors now owns 5,578,232 shares of the company’s stock valued at $381,272,000 after acquiring an additional 247,254 shares during the last quarter. BlackRock Inc. raised its stake in Biohaven Pharmaceutical by 7.3% during the 1st quarter. BlackRock Inc. now owns 3,783,554 shares of the company’s stock valued at $258,608,000 after acquiring an additional 258,603 shares during the last quarter. Stifel Financial Corp raised its stake in Biohaven Pharmaceutical by 0.9% during the 1st quarter. Stifel Financial Corp now owns 2,564,822 shares of the company’s stock valued at $175,306,000 after acquiring an additional 22,348 shares during the last quarter. Alliancebernstein L.P. raised its stake in Biohaven Pharmaceutical by 20.9% during the 1st quarter. Alliancebernstein L.P. now owns 1,456,559 shares of the company’s stock valued at $99,556,000 after acquiring an additional 251,355 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Biohaven Pharmaceutical by 46.3% during the 1st quarter. Bank of New York Mellon Corp now owns 1,187,193 shares of the company’s stock valued at $81,145,000 after acquiring an additional 375,612 shares during the last quarter. 92.14% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:BHVN opened at $132.57 on Tuesday. The business’s fifty day moving average price is $125.85 and its two-hundred day moving average price is $97.32. The stock has a market cap of $8.67 billion, a PE ratio of -9.25 and a beta of 1.03. Biohaven Pharmaceutical Holding Company Ltd. has a one year low of $57.70 and a one year high of $139.66.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Sunday, August 8th. The company reported ($3.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.77) by ($0.46). The business had revenue of $92.93 million during the quarter, compared to analysts’ expectations of $85.85 million. The business’s revenue was up 858.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.55) EPS. As a group, equities analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -12.17 EPS for the current year.

BHVN has been the subject of a number of analyst reports. Morgan Stanley increased their target price on Biohaven Pharmaceutical from $69.00 to $107.00 and gave the stock an “equal weight” rating in a research note on Friday, July 16th. Canaccord Genuity increased their target price on Biohaven Pharmaceutical from $101.00 to $150.00 and gave the stock a “buy” rating in a research note on Tuesday, August 3rd. Zacks Investment Research raised Biohaven Pharmaceutical from a “strong sell” rating to a “hold” rating and set a $123.00 target price for the company in a research note on Monday, July 12th. HC Wainwright increased their target price on Biohaven Pharmaceutical from $111.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 8th. Finally, Mizuho increased their target price on Biohaven Pharmaceutical from $92.00 to $134.00 and gave the stock a “buy” rating in a research note on Monday, July 12th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $124.27.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.

Further Reading: Fibonacci Channel

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.